500
Participants
Start Date
August 1, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2029
rt-PA
Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.
DAPT
Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.
RECRUITING
Fukuoka Red Cross Hospital, Fukuoka
RECRUITING
Ota Memorial Hospital, Fukuyama
RECRUITING
Kagoshima City Hospital, Kagoshima
RECRUITING
Kagoshima Medical Center, Kagoshima
RECRUITING
Shioda Hospital, Katsuura
RECRUITING
Kohnan Hospital, Sendai
RECRUITING
Nippon Medical School Tamanagayama hospital, Tama
RECRUITING
Dokkyo Medical University Hospital, Tochigi
RECRUITING
Tokushima University Hospital, Tokushima
RECRUITING
Juntendo University Hospital, Tokyo
RECRUITING
Nippon Medical School hospital, Tokyo
RECRUITING
Tokyo Saiseikai Central Hospital, Tokyo
RECRUITING
Juntendo University Urayasu Hospital, Urayasu
Lead Sponsor
Japan Research Foundation for Clinical Pharmacology
UNKNOWN
Takeda Science Foundation - Medical Research Grant
UNKNOWN
Nippon Medical School
OTHER